Amplify Weight Loss Drug & Treatment ETF Rating $24.74 +0.57 (+2.36%) As of 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatings Amplify Weight Loss Drug & Treatment ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.THNR Aggregate RatingModerate Buy 2.58Holdings in THNR have an aggregate rating of Moderate Buy based on 277 analyst ratings issued in the past year covering 12 companies (63.2% of the portfolio).THNR Aggregate Price Target$24.74High Prediction$24.74Average Prediction$24.74Low Prediction$24.74Holdings in THNR have an aggregate price target of $24.74 and a range of $24.74 to $24.74 covering 12 companies (63.2% of the portfolio).THNR Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy0 Buy rating(s)Moderate Buy9 Moderate Buy rating(s)Hold3 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Amplify Weight Loss Drug & Treatment ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 12 THNR Holdings ExportWeight In ETFCompanyShare PriceConsensus RatingConsensus Price TargetPossible UpsideNumber of RatingsMarketRank™Indicator(s)ViewRatings10.20%LLYEli Lilly and Company$1,253.94+3.7%Moderate Buy$1,313.43 4.7%294.8026 of 5 starsTrending NewsAnalyst ForecastAnalyst RevisionGap Up8.50%NVONovo Nordisk A/S$39.22+2.9%Hold$59.44 51.5%264.0953 of 5 starsAnalyst ForecastAnalyst RevisionGap Up5.63%AMGNAmgen$434.03+1.9%Hold$387.93 -10.6%303.9627 of 5 starsTrending NewsAnalyst ForecastAnalyst RevisionGap Up5.37%PFEPfizer$29.47+0.9%Hold$28.72 -2.5%212.9117 of 5 starsTrending NewsAnalyst ForecastOptions VolumeAnalyst Revision5.36%ABBVAbbVie$283.07-0.1%Moderate Buy$277.18 -2.1%304.6302 of 5 starsTrending NewsAnalyst ForecastOptions VolumeAnalyst Revision5.20%GILDGilead Sciences$157.37+2.5%Moderate Buy$159.33 1.2%293.0711 of 5 starsTrending NewsAnalyst ForecastAnalyst Revision5.18%MRKMerck & Co., Inc.$145.66-1.2%Moderate Buy$151.92 4.3%274.5931 of 5 starsAnalyst ForecastAnalyst Revision4.96%REGNRegeneron Pharmaceuticals$796.34+2.3%Moderate Buy$845.21 6.1%314.4894 of 5 starsTrending NewsAnalyst UpgradeInsider TradeGap Up4.84%VKTXViking Therapeutics$27.37+7.5%Moderate Buy$98.90 261.3%143.5288 of 5 starsTrending NewsAnalyst UpgradeGap Up4.03%ARWRArrowhead Pharmaceuticals$58.50+0.2%Moderate Buy$99.07 69.4%152.6835 of 5 starsTrending NewsAnalyst Forecast2.99%GPCRStructure Therapeutics$22.19+1.4%Moderate Buy$110.91 399.8%172.1082 of 5 stars0.92%KLRAKailera Therapeutics$11.71+9.0%Moderate Buy$42.75 265.1%82.3828 of 5 starsLockup Expiration This page (NYSEARCA:THNR) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amplify Weight Loss Drug & Treatment ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Amplify Weight Loss Drug & Treatment ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free THNR Stock Alerts